)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Chimerix
Chimerix (CMRX) investor relations material
Chimerix has been delisted
Chimerix Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary21 Mar, 2025
Executive summary
FDA accepted NDA for dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma; PDUFA action date set for August 18, 2025.
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, totaling ~$935 million; expected to close in Q2 2025.
Chimerix continues to advance dordaviprone and ONC206 clinical programs.
Financial highlights
Q4 2024 net loss was $23.0 million ($0.25/share) vs. $18.2 million ($0.20/share) in Q4 2023.
Full-year 2024 net loss was $88.4 million ($0.99/share) vs. $82.1 million ($0.93/share) in 2023.
Q4 2024 R&D expenses rose to $17.7 million from $15.6 million year-over-year; G&A expenses increased to $7.0 million from $5.2 million.
Full-year 2024 R&D expenses were $74.6 million, up from $68.8 million; G&A expenses decreased to $22.2 million from $24.6 million.
Cash and investments totaled $140.1 million at year-end 2024; no outstanding debt.
Outlook and guidance
Preparing for potential commercial launch of dordaviprone, pending FDA approval.
Anticipates closing of Jazz acquisition in Q2 2025, subject to customary conditions.
Rationale for dordaviprone launch prep spend
Explain full-year G&A decrease vs Q4 increase
Is current capital sufficient until PDUFA date?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chimerix
- Phase III glioma trial nears key survival data; ONC206 and Australia approval advance in 2024.CMRX
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q2 net loss $20.7M as late-stage oncology trials progress; cash runway extends into Q4 2026.CMRXQ2 20241 Feb 2026
- Dordaviprone advances to phase III with strong data; ONC206 and TEMBEXA add pipeline and financial strength.CMRXH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Q3 net loss narrowed to $22.9M as dordaviprone and ONC206 clinical programs advanced.CMRXQ3 202416 Jan 2026
- Dordaviprone NDA targets Q3 2025 FDA approval, backed by 28% response rate and strong safety.CMRXFDA Announcement11 Jan 2026
Chimerix
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage